- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03186417
Mesenchymal Stem Cells in Early Rheumatoid Arthritis
Cell-Based Therapy in Rheumatoid Arthritis: Proof of Concept Phase 1 Trial
This is a prospective, multicenter, double-blind, placebo controlled interventional study to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSCs) in 20 patients with new onset Rheumatoid Arthritis (RA). The study is a single dose, phase I clinical trial and is the first time that this product will be infused in RA patients. The study duration is approximately fourteen months from time of screening to completion.
Research hypothesis: The investigators hypothesize that when administered therapeutically, MSCs will induce healthy immune responses and will reduce RA disease activity. This study is primarily focused on demonstrating the safety of this approach.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Nora Singer, MD
- Phone Number: 216-778-2323
- Email: nsinger@metrohealth.org
Study Contact Backup
- Name: Larraine Gordesky, MS, RN, BSN
- Phone Number: 216-778-8927
- Email: lgordesky1@metrohealth.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, United States, 44106
- UH Hospitals Cleveland
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18-80 years
- Recent onset rheumatoid arthritis and have known doctor diagnosis ≤ 2 years and symptoms for ≤ 2 years.
- Patients must have detectable serum auto-antibodies against cyclic citrullinated peptides and/or high titer serum rheumatoid factor at screening or prior to screening.
- Subjects must have active synovitis of at least one joint.
- Patients who have been intolerant or had inadequate response to at least twelve weeks total of methotrexate, ten weeks of which methotrexate must have been dosed at ≥15 mg per week or with low dose steroids (< 10 mg prednisone per day).
- Clinically stable with no significant changes in health status within 2 weeks prior to randomization
Exclusion Criteria:
- Prior use of DMARDs other than non-steroidals, low dose prednisone, hydroxychloroquine and methotrexate
- Use of leflunomide or sulfasalazine for more than 3 days and less than 3 half lives have passed since discontinuing. For leflunomide, wash out is permissible.
- Prior use of Biologic DMARDs
- Presence of active infection
- History of chronic viral infections including Hepatitis B or C or HIV. Treated Hepatitis C is allowed if the viral in non-detectable
- Known chronic liver disease
- Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study and for twelve months after completing the study infusion, unless surgically sterilized or postmenopausal during the study.
- Active tuberculosis (TB) requiring treatment within 3 years prior to baseline
- Latent TB diagnosed during screening that has not been appropriately treated
- History of Cancer requiring chemotherapy within the past 5 years except Human Papillomavirus (HPV) related cervical changes that are not carcinoma in situ.
- Chronic obstructive pulmonary disease or known lung disease except for mild asthma treated with bronchodilators.
- Use of an investigational agent within the 4-week period prior to screen
- If Dimethyl sulfoxide (DMSO) is used in the preparation of MSCs then subjects with known sensitivity to DMSO will be excluded
- History of Transient Ischemic Attack
- History of Cerebrovascular Accident (stroke), unless there has been no CVA for > or = 1 year after the resolution of the underlying cause of the CVA
- Clinically significant heart disease (New York Heart Association, class III and class IV).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
2 million human MSC (hMSC)/kg infusion versus placebo infusion
|
2 million hMSCs/kg infusion
placebo infusion
|
Experimental: Cohort 2
4 million hMSC/kg infusion versus placebo infusion
|
placebo infusion
4 million hMSC/kg infusion
|
Experimental: Cohort 3
6 million hMSC/kg infusion versus placebo infusion
|
placebo infusion
6 million hMSC/kg infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety assessed by dose limiting toxicity (DLT)
Time Frame: 14 days following infusion
|
• In addition, a DLT will be assigned if through 14 days after the infusion any grade 3-4 adverse event for pulmonary, cardiac, renal, oral mucosal or hepatic, and grade 4 adverse events for other organs occurred per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
|
14 days following infusion
|
Safety assessed by dose limiting toxicity
Time Frame: 48 hours following infusion
|
• A DLT is triggered by occurrence through 48 hours after infusion of grade ≥2 infusion-related allergic toxicities, which include rash, flushing, urticaria, dyspnea, fever ≥38°C (≥100.4°F)
as scored according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events (CTCAE) version 4.03.
|
48 hours following infusion
|
Safety assessed by change in spirometry
Time Frame: 30 minutes following infusion
|
• Changes in spirometry following infusion compared to baseline
|
30 minutes following infusion
|
Safety assessed by all adverse events
Time Frame: 52 weeks following infusion
|
• Incidence and severity of adverse events
|
52 weeks following infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in patient reported outcomes
Time Frame: Up to day 28 after infusion
|
2. Change in patient reported outcomes (PROMIS CAT and legacy [RAPID 3 / SF36] -questionnaires)
|
Up to day 28 after infusion
|
DAS28-CRP
Time Frame: Week 52
|
Changes in DAS28-CRP
|
Week 52
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nora singer, MD, MetroHealth Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB16-00587
- R21AR069226 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on 2 million hMSC/kg
-
Bernard (Barry) BaumelCompleted
-
Ruijin HospitalCellular Biomedicine Group Ltd.UnknownAcute Respiratory Distress SyndromeChina
-
National Institute of Allergy and Infectious Diseases...University of PittsburghRecruitingKidney Transplant | Renal Transplant RecipientsUnited States
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompletedAmyotrophic Lateral SclerosisSpain
-
Astellas Pharma Global Development, Inc.CompletedCLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction | CLDN18.2-positive Adenocarcinoma of Esophagus | CLDN18.2-positive Gastric AdenocarcinomaGermany, Latvia
-
Tunitas Therapeutics, Inc.Tunitas Therapeutics Australia Pty LtdTerminatedAllergy and ImmunologyAustralia
-
Keymed Biosciences Co.LtdNot yet recruitingSystemic Lupus Erythematosus
-
Minia UniversityCompleted
-
PfizerWithdrawnDyslipidemia | Hypercholesterolemia
-
Crucell Holland BVNational Institute of Allergy and Infectious Diseases (NIAID)Completed